Nucleic acid aptamers, often termed 'chemical antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability and lack of immunogenicity. In addition, many aptamers are internalized upon binding to cellular receptors, making them useful targeted delivery agents for small interfering RNAs (siRNAs), microRNAs and conventional drugs. However, several crucial factors have delayed the clinical translation of therapeutic aptamers, such as their inherent physicochemical characteristics and lack of safety data. This Review discusses these challenges, highlighting recent clinical developments and technological advances that have revived the impetus for this promising class of therapeutics.
chemical production 0.9999999999985221^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Chemical_industry     

chemical modification         0.9999999999980673^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Chemical_synthesis    

cellular receptors            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Receptor_(biochemistry)

antibodies                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antibody              

aptamers                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aptamer               

aptamers                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aptamer               

small interfering RNAs        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Small_interfering_RNA 

targeted delivery             1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Targeted_drug_delivery

drugs                         0.9956901749347776^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Drug                  

chemical                      0.6759633912877929^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Chemical_compound     

immunogenicity                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Immunogenicity        

Nucleic acid                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Nucleic_acid          

safety                        0.9999983382854389^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

siRNAs                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Small_interfering_RNA 

physicochemical               0.9880768647973641^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Physical_chemistry    

microRNAs                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/MicroRNA              

therapeutics                  0.9999999999876081^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Therapy               

antibodies                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antibody              

aptamers                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Aptamer               

translation                   0.9999999997717168^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Translation_(biology) 

